Get the Stockscreener App
1.07
1.83%
-0.02
Context Therapeutics Inc stock is traded at $1.07, with a volume of 76,330.
It is down -1.83% in the last 24 hours and down -2.73% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$1.09
Open:
$1.1
24h Volume:
76,330
Relative Volume:
0.27
Market Cap:
$95.80M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-1.1758
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-13.01%
1M Performance:
-2.73%
6M Performance:
+23.05%
1Y Performance:
-52.86%
1-Day Range:
$1.05
$1.12
1-Week Range:
$1.05
$1.256
52-Week Range:
$0.49
$2.3257
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.068 | 97.78M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.80 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.61 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.11 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Is Context Therapeutics Inc. stock a defensive play in 2025Quarterly Market Summary & Verified Chart Pattern Signals - newser.com
Is Context Therapeutics Inc. stock a safe buy before earningsJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Is Context Therapeutics Inc. stock poised for growth2025 Growth vs Value & Long-Term Growth Stock Strategies - newser.com
Is Context Therapeutics Inc. stock positioned well for digital economyInsider Buying & Reliable Breakout Forecasts - newser.com
Is Context Therapeutics Inc. a candidate for recovery play2025 Performance Recap & AI Forecast Swing Trade Picks - newser.com
Why analysts remain bullish on Context Therapeutics Inc. stockWall Street Watch & Intraday High Probability Alerts - newser.com
Using portfolio simulators with Context Therapeutics Inc. includedJuly 2025 Selloffs & Verified Trade Idea Suggestions - newser.com
Is Context Therapeutics Inc. trending in predictive chart modelsWeekly Market Report & Verified Stock Trade Ideas - newser.com
Context Therapeutics Inc. stock trendline breakdownDividend Hike & Proven Capital Preservation Tips - newser.com
Does Context Therapeutics Inc. stock trade at a discount to peersWeekly Risk Report & AI Forecast for Swing Trade Picks - newser.com
Applying chart zones and confluence areas to Context Therapeutics Inc.July 2025 Review & Consistent Profit Trade Alerts - newser.com
Is Context Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Movers & Real-Time Volume Analysis - newser.com
Real time scanner hits for Context Therapeutics Inc. explained2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
What’s the recovery path for long term holders of Context Therapeutics Inc.Trade Performance Summary & Precise Swing Trade Alerts - newser.com
What recovery options are there for Context Therapeutics Inc.Portfolio Gains Report & Comprehensive Market Scan Reports - newser.com
Is Context Therapeutics Inc. stock resilient to inflationWeekly Trade Analysis & Fast Exit and Entry Strategy Plans - newser.com
Context Therapeutics Grants Stock Options to New Hire - MSN
How to interpret RSI for Context Therapeutics Inc. stockM&A Rumor & Weekly High Conviction Ideas - newser.com
Why hedge funds are buying Context Therapeutics Inc. stockEarnings Recap Summary & Precise Trade Entry Recommendations - newser.com
Exit strategy if you’re trapped in Context Therapeutics Inc.July 2025 EndofMonth & Comprehensive Market Scan Insights - newser.com
What drives Context Therapeutics Inc stock priceEnergy Sector Updates & Small Budget Trading Ideas - earlytimes.in
Context Therapeutics (CNTX) Projected to Post Earnings on Wednesday - MarketBeat
Statistical indicators supporting Context Therapeutics Inc.’s strengthTake Profit & Weekly High Potential Alerts - newser.com
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):